about
The MIP-1α autocrine loop contributes to decreased sensitivity to anticancer drugs.Pioglitazone inhibits cancer cell growth through STAT3 inhibition and enhanced AIF expression via a PPARγ-independent pathway.RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cellsOverexpression of HIF-1α contributes to melphalan resistance in multiple myeloma cells by activation of ERK1/2, Akt, and NF-κBTamoxifen suppresses paclitaxel-, vincristine-, and bortezomib-induced neuropathy via inhibition of the protein kinase C/extracellular signal-regulated kinase pathwayDasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cellsInhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cellsCombination therapy with dacarbazine and statins improved the survival rate in mice with metastatic melanoma
P50
Q47618731-49F04B1A-314F-4FD1-B2BA-C8DAD5905501Q48186804-8AEF74C2-42BC-45C5-9A2B-6EF93E0C39CCQ57021446-C2CA5EF1-3692-4BBA-A8D9-71B2739FF82DQ57798467-994CD2AD-CA39-447D-91DA-AFFB6F3C8E07Q58602933-44DE7CC7-9C39-43D0-ACB0-DA6CF57A624CQ90324805-620D272F-FADC-4EC3-BA0A-9F9F828887DCQ90934553-5EBF605B-683D-4D45-A7DB-4E740B25F306Q92133289-6C1CDA78-33AB-48A6-97B5-33CDFF6E9C34
P50
description
researcher
@en
wetenschapper
@nl
name
Shozo Nishida
@en
Shozo Nishida
@nl
type
label
Shozo Nishida
@en
Shozo Nishida
@nl
prefLabel
Shozo Nishida
@en
Shozo Nishida
@nl
P31
P496
0000-0002-3408-0462